Teva Pharmaceutical Indus에 대한 매도 수량은 투자자에게 Teva Pharmaceutical Indus의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

News

Movers

EQIX

TEVA

TOST

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?테바 파마슈티컬 인더스트리즈(NYSE:TEVA)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 위약과 비교하여 정신분열증이 있는 성인 환자를 대상으로 한 TEV-&#39;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다. 

지난주(5월 5일~5월 11일) 최고의 성과를 낸 10개의 대형주

Earnings

Pre-Market Outlook

Markets

Trading Ideas

LYFT

UBER

수요일 오전(현지 시간) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월가는 수요일 개장 전 분기 실적 발표로 에머슨 일렉트릭(NYSE:EMR)이 매출 42억 9천만 달러, 주당 1.25달러의 분기 이익을 보고할 것으로 예상한다. 에머슨 일렉트릭의 주식은 시간외 거래에서 1.2% 오른 108.70달러에 거래되었다. 

우버, 리프트 그리고 수요일에 주목해야 할 3개의 주식

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARMA IND ADR REP 1 ORD

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

<ul>
<li>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</li>
<li>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</li>
<li>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</li>
</ul>
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Biotech

General

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

<ul>
<li>Teva's presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience</li>
<li>Data show TEV-'749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date</li>
<li>Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults with schizophrenia who have barriers to treatment &nbsp;</li>
</ul>
TEL AVIV, Israel &amp; PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.
Schizophrenia is a complex medical condition which can severely impact quality of life and social functioning. These new results demonstrate the potential benefits TEV-'749 may have for patients utilizing this form of a long-acting injectable (LAI) treatment option including improving quality life and social functioning.1

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results Of Real-World Analyses Of UZEDY; Analysis Of UZEDY Highlights High Adherence And Usage Among Patients With Treatment Barriers

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has outperformed the market over the past 5 years by 2.31% on an annualized basis producing an average annual return of 15.92%. Currently, Teva Pharmaceutical Indus has a market capitalization of $20.87 billion. 
Buying $1000 In TEVA: If an investor had bought $1000 of TEVA stock 5 years ago, it would be worth $2,205.99 today based on a price of $18.42 for TEVA at the time of writing.
<h3>Teva Pharmaceutical Indus's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730219415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.75, a high estimate of $26.00, and a low estimate of $18.00. Marking an increase of 9.64%, the current average surpasses the previous average price target of $20.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1729692010_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Teva Pharmaceutical Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Teva Pharmaceutical Indus's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Discovering Teva Pharmaceutical Indus: A Closer Look</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Breaking Down Teva Pharmaceutical Indus's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.4% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -20.32%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.41%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio is below the industry average at 2.98, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Overweight and raises the price target from $22 to $25.

Price Target

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $25

This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara&reg;&nbsp;(ustekinumab) in the U.S. at launch, which is expected in the&nbsp;first quarter&nbsp;of 2025.

ALVO

Alvotech, Teva Reports FDA Approval For SELARSDI (Ustekinumab-aekn) In New Presentation, 130 Mg/26 Ml (5 Mg/Ml) Solution In Single-dose Vial For Intravenous Infusion

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Neutral and raises the price target from $16 to $18.

JP Morgan Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $18

On Thursday, Amicus Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
The <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41376664/amicus-therapeutics-announces-settlement-of-galafold-migalastat-patent-litigation-with-teva" rel="noreferrer noopener">agreement resolves</a> the patent litigation brought by Amicus in response to Teva&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Galafold (migalastat) 123mg capsules before the expiration of the applicable patents.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41295664/teva-pays-450m-to-resolve-alleged-kickback-price-fixing-schemes" rel="noreferrer noopener">Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes</a>.
Galafold is a medication for Fabry disease, a rare genetic disorder caused by the buildup of a type of fat called globotriaosylceramide in the body&#8217;s cells.
Under the terms of the Agreement, Amicus will grant Teva a license to market its generic version of Galafold&nbsp;in the&nbsp;United States&nbsp;beginning on January 30, 2037, if approved by the FDA and unless certain limited circumstances customarily included in these types of agreements occur.
The parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding Galafold patents pending in the U.S. District Court for the District of Delaware.
The litigation will continue against Aurobindo&nbsp;as the remaining active party, and the litigation stay remains in place for Lupin.
Price Action: TEVA stock is up 0.47% at $18.11, and FOLD stock is up 12.4% at $11.81 at last check Thursday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41381891/commercial-metals-q4-eps-beats-by-a-whisker-but-outlook-signals-tough-start-to-2025" target="_blank" rel="noreferrer noopener">Commercial Metals Q4 EPS Beats By A Whisker, But Outlook Signals Tough Start To 2025</a>.</li>
</ul>

Equities

Health Care

Legal

FOLD

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

This Agreement resolves the patent litigation brought by Amicus in response to Teva&#39;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of GALAFOLD&nbsp;(migalastat) 123mg capsules prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD&nbsp;in the&nbsp;United States&nbsp;beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration (FDA) and unless certain limited circumstances customarily included in these types of agreements occur.
In accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding GALAFOLD&nbsp;patents pending in the U.S. District Court for the District of Delaware. The litigation will continue against Aurobindo1&nbsp;as the remaining active party and the litigation stay remains in place for Lupin.

Amicus Therapeutics Enters License Agreement With Teva, Resolving Galafold Patent Litigation; No Terms Disclosed

Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40801368/teva-announces-80m-settlement-to-baltimore-city-continues-opioid-litigation-against-other-compani" rel="noreferrer noopener">False Claims Act (FCA)</a>.
The settlement stems from claims that Teva engaged in two unlawful kickback schemes, impacting Medicare and the pricing of essential drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40957505/eli-lilly-fights-183m-medicaid-fraud-judgment-cites-reasonable-interpretation-of-medicaid-rules" rel="noreferrer noopener">Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules</a>.
This resolution includes $225 million in criminal penalties that Teva USA previously paid as part of a deferred prosecution agreement with the Department of Justice.
The first kickback <a target="_blank" href="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback" rel="noreferrer noopener">scheme</a> involved allegations that Teva violated the AKS by covering Medicare patients&#8217; copays for the multiple sclerosis drug Copaxone between 2006 and 2017.
During this period, Teva is accused of coordinating with third parties, including a specialty pharmacy and two supposedly independent copay assistance foundations, to direct donations to cover patients&#8217; Copaxone copays.
According to federal prosecutors, these actions were prohibited by the AKS and caused false claims to be submitted to Medicare as Teva simultaneously raised the drug&#8217;s price.
The second scheme alleges that Teva USA conspired with other generic drug manufacturers to fix the prices of pravastatin, a cholesterol-lowering drug, clotrimazole, and tobramycin, two additional generics.
The Justice Department had previously secured a deferred prosecution agreement with Teva USA, where the company admitted to participating in price-fixing activities.
The settlement is part of a broader initiative against price-fixing and kickbacks in the pharmaceutical industry.
According to Joshua S. Levy, Acting U.S. Attorney for the District of Massachusetts, Teva&#8217;s manipulation of the charitable foundation process violated the AKS and undermined Medicare&#8217;s copay system. His office has played a central role in these enforcement actions, returning over $1 billion to Medicare since 2017.
This settlement is the largest among a series of cases targeting pharmaceutical companies that unlawfully paid patient copays through third-party foundations.
The Justice Department has secured over $1 billion from these companies and reached settlements with four foundations and a specialty pharmacy.
Price Action: TEVA stock is down 0.34% at $17.35 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41289783/jpmorgan-chase-q3-earnings-investment-banking-revenue-soars-29-raises-fy24-net-interest-income-outl" target="_blank" rel="noreferrer noopener">JPMorgan Chase Q3 Earnings: Investment Banking Revenue Soars 29%, Largest Bank Raises Net Interest Income Outlook</a>.</li>
</ul>

Large Cap

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes

<a href="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback" title="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback">https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback</a>

'Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing' - DOJ

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has outperformed the market over the past 5 years by 6.31% on an annualized basis producing an average annual return of 20.33%. Currently, Teva Pharmaceutical Indus has a market capitalization of $19.92 billion. 
Buying $100 In TEVA: If an investor had bought $100 of TEVA stock 5 years ago, it would be worth $261.22 today based on a price of $17.58 for TEVA at the time of writing.
<h3>Teva Pharmaceutical Indus's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728572432_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

The FDA&#39;s anticipated decision and EMA&#39;s expected opinion are anticipated in the second half of 2025.

Teva Says FDA Has Accepted, And The European Medicines Agency Has Validated, Applications For TVB-009P, A Biosimilar Candidate To Prolia

Macro Notification

DARE

PGNY

PRGO

US State Of Georgia's Supreme Court Reinstates Abortion Ban That Was Blocked By Lower Court

On Wednesday, the U.S. Department of Health and Human Services (HHS), working via the Centers for Medicare &amp; Medicaid Services (CMS), released final guidance for the second cycle of the <a href="https://www.benzinga.com/general/health-care">Medicare Drug Price Negotiation Program</a>.
This initiative <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
It also ensures that people with Medicare can access these negotiated prices, expanding on the groundwork laid in the first cycle of negotiations.
The first round of negotiations focused on 10 specific drugs. Medicare recipients should save approximately $1.5 billion in out-of-pocket costs when the new prices take effect in 2026.
By February 2025, CMS will select up to 15 additional drugs for the second round of negotiations. The selected drugs will undergo negotiations in 2025, with new prices becoming effective in 2027.
They include: 
<ul>
<li>Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes drug, <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">Ozempic,</a></li>
<li>Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer drugs Ibrance and Xtandi</li>
<li>GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) asthma treatment Trelegy Ellipta</li>
<li>Teva Pharmaceutical Industries Ltd.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington&#8217;s disease drug Austedo, and</li>
<li>Abbvie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess.</li>
</ul>
CMS plans to improve patient-focused engagement during the second cycle of negotiations. It will also organize roundtable events and town hall meetings in 2025.
As Medicare Open Enrollment approaches on Oct. 15, beneficiaries can expect more cost-saving measures in the coming years. That includes a $2,000 annual cap on out-of-pocket drug costs starting in January 2025.
These changes build on other provisions of the Inflation Reduction Act, which was signed by President Joe Biden on Aug. 16, 2022. The legislation included a $35 monthly cap on insulin and free recommended vaccines for adults covered under Medicare Part D.
Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from Oct. 1, 2024, to Dec. 31, 2024. Some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could" target="_blank" rel="noreferrer noopener">in the rebate program</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41162084/amazon-prime-video-ramps-up-ads-taking-on-netflix-and-disney-in-streaming-battle" target="_blank" rel="noreferrer noopener">Amazon Prime Video Ramps Up Ads, Taking on Netflix and Disney+ in Streaming Battle</a>.</li>
</ul>
Image: Shutterstock

Government

ABBV

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected

<ul>
<li>The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024</li>
<li>The collaboration supports Teva's Pivot to Growth strategy and adds to the company's biosimilar portfolio</li>
<li>Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide &nbsp;</li>
</ul>
TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.
The global agreement to develop an additional oncology biosimilar further strengthens the alliance between Teva and mAbxience, underscoring the shared goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging each company's unique expertise and resources, the collaboration continues to drive innovation and accessibility in healthcare to create solutions for patients worldwide.
The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion. The collaboration reflects Teva's progress advancing its Pivot to Growth strategy by adding a new biosimilar to the company's broad portfolio of biosimilars, through focused partnerships and business development efforts.

Teva And mAbxience Expand Strategic Partnership To Include An Additional Oncology Biosimilar Candidate; Both Companies Reaffirm Their Shared Commitment To Making High-Quality, Affordable Treatments Accessible To Patients Worldwide

Shares of Teva Pharmaceutical Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) on Tuesday the launch of the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S.
Teva's new generic drug is used to treat acromegaly—a condition characterized by excessive growth hormone—and severe diarrhea in patients with carcinoid syndrome, a complication of certain cancers. With annual sales of $826 million for the brand-name version of Sandostatin LAR Depot as of July 2024, the new generic option is expected to provide more affordable treatment to patients.
Ernie Richardsen, SVP of U.S. Commercial Generics at Teva, expressed optimism about the launch, stating, "This first-to-market launch showcases Teva&#8217;s expertise in bringing complex generics to market. We are not only sustaining a generics powerhouse but also bringing value to patients and healthcare systems."
What Else: Iran&#8217;s <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41120592/iran-set-to-launch-ballistic-missile-attack-against-israel-report">missile attack</a> on Teva&#8217;s home country of Israel may have also be impacting the stock today. 
TEVA Price Action: Teva shares were down by 2.6% at $254.81 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01132741/TEVA-1024x550.png" alt="" class="wp-image-575213" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01132741/TEVA-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01132741/TEVA-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01132741/TEVA-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01132741/TEVA.png 1056w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41125099/ripple-receives-dubai-approval-for-blockchain-payment-services">Ripple Receives Dubai Approval For Blockchain Payment Services</a></li>
</ul>
Image Via Shutterstock.

Teva Launches Generic Version Of Sandostatin In The US

<ul>
<li>This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse. &nbsp;</li>
<li>Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.</li>
</ul>
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin&#xAE;1 LAR Depot, in the United States.
Octreotide acetate for injectable suspension (the generic version of Sandostatin&#xAE; LAR Depot) is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Please see the below for more information.

Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has outperformed the market over the past 5 years by 6.63% on an annualized basis producing an average annual return of 20.77%. Currently, Teva Pharmaceutical Indus has a market capitalization of $19.95 billion. 
Buying $1000 In TEVA: If an investor had bought $1000 of TEVA stock 5 years ago, it would be worth $2,544.03 today based on a price of $17.61 for TEVA at the time of writing.
<h3>Teva Pharmaceutical Indus's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727724615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today

Truist Securities raised the price target for Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it &#8220;is impressive and difficult to ignore.&#8221;
Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed.&nbsp;
Cushing syndrome is&nbsp;a hormonal disorder that occurs when the body has too much cortisol, a hormone that helps the body respond to stress.&nbsp;
Truist analyst notes approximately 20K Cushing&#8217;s disease (pituitary adenoma) patients in the U.S., of which ~10K are adequately managed with surgical resection of the pituitary adenoma.
Medical management is recommended for the remaining 10K. Therefore, there&#8217;s still significant room for growth, with just ~2,000 hypercortisolism patients currently on Korlym.
In June, Teva Pharmaceuticals Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reportedly sued Corcept Therapeutics, accusing it of a monopoly on Korlym.
The lawsuit, filed in federal court in San Francisco, alleges that Corcept and its sole distributor, Optime Care, engaged in anti-competitive practices <a target="_blank" href="https://www.benzinga.com/24/06/39339275/concerpt-therapeutics-shares-are-trading-lower-what-you-need-to-know" rel="noreferrer noopener">to stifle competition</a>.
In May,&nbsp;Corcept Therapeutics announced that the GRACE Phase 3 trial of&nbsp;relacorilant&nbsp;in patients with hypercortisolism (Cushing&#8217;s syndrome)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39039282/why-mid-cap-corcept-therapeutics-stock-trading-higher-on-tuesday" rel="noreferrer noopener">met its primary endpoint</a>.
The company is conducting a Phase 3 GRADIENT trial for relacorilant with enrolled adrenal adenoma patients to strengthen the case for treating patients whose hypercortisolism was driven by adrenal adenoma.
Data from GRACE and GRADIENT studies will form a part of the FDA application submission. The analyst says, &#8220;GRADIENT is well-powered for success.&#8221;
Truist notes that Corcept Therapeutics can achieve around $3 billion in total revenue within five years.
The analyst highlights that management emphasized that once relacorilant is approved, almost all existing patients on Korlym would be converted to relacorilant.
With increased market penetration of relacorilant in Cushing&#8217;s from 16% to 25% in 2033, Truist raised the price target from $65 to $76, <a target="_blank" href="https://www.benzinga.com/quote/CORT/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: CORT stock is up 5.19% at $46.21 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41101457/optimism-around-aquestive-as-it-moves-forward-with-severe-allergy-baldness-candidat" target="_blank" rel="noreferrer noopener">Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate</a>.</li>
</ul>

Analyst Color

Reiteration

CORT

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

Barclays raised the firm's price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine...

Teva price target raised to $25 from $22 at Barclays

Teva (TEVA) Pharmaceuticals Industries is responding to the European Decision following its investigation into the company's practices regarding CO...

Teva issues a statement on the European Commission's decision on COPAXONE

Teva fined $500M by European Commission for disparaging rival MS drug

Teva fined $500M by EU for disparaging rival MS drug (update)

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new, "positive" data on social functioning and quality o...

Teva presents Phase 3 SOLARIS trial results

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new patient- and physician-reported interim results from...

Teva presents new Tardive Dyskinesia data at Psych Congress

Teva long-acting olanzapine shows improvements in schizophrenia patients

Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more

Teva Pharmaceutical Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

ABNB

ABUS

ADRNY

AFRM

ANET

ATHM

AUDC

BLNK

BMWYY

BNTX

BYND

CELH

CLBT

CNDT

CRSP

CTVA

DDOG

DKNG

EHTH

ENOV

FANG

GILD

HENKY

ILMN

IONS

LCID

LNTH

LUMN

MAIN

MARA

MCFT

MKTX

MOGO

MRNA

NEON

NVAX

NXPI

OESX

OPEN

PARA

PERI

PFGC

PINS

PLTR

QCOM

RIVN

RPRX

SEDG

SNDR

SONY

SPCE

STWD

TCPC

TRMB

TTWO

TWLO

UPST

URGN

VONOY

VRNOF

VRTX

VTRS

WYNN

Press Releases

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Teva Statement on European Commission Decision; Company to Appeal

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Comments

Teva Pharmaceutical Indus

매도 수량

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌